The company plans to recover the volume of available seats they had between Mexico and Canada in 2019 by the end of next year.
The airline Air Canada assured that at this time it does not have plans to operate at the Felipe Ángeles International Airport (AIFA), since there are still no studies that confirm the viability of flying to the terminal being built in Santa Lucia, a government priority project by Andrés Manuel López Obrador when we have the information.
“As for the Felipe Ángeles, we are not contemplating it at the moment, there is a long way to go, it is not finished, we need to do feasibility studies and studies of the capacity of the Mexico City International Airport (AICM) so it is not in our plans” said the director of sales for Latin America and the Caribbean, Luis Noriega.
This is after the Ministry of Communications and Transportation (SCT) announced yesterday that it will limit flights to the AICM between 2022 and 2023 to 61% of operations, with the objective that companies fly to AIFA.
In a conference, Noriega highlighted that the routes to Mexico City were among the 5 Air Canada routes that the company did not stop operating worldwide, despite all the restrictions in the Canadian market, due to the need to attend to traffic. business essentials, students, and first-degree family visits.
In fact, at the end of last month they flew back to Cancun and hope to regain routes to beach destinations in the remainder of the year or early 2022; In addition, they plan to recover the volume of available seats they had in 2019 at the end of next year .
“It is difficult to make exact projections due to the characteristics of this pandemic, but I bet that by the end of next year we should already have the volume of seats available that we had in 2019 between Mexico and Canada,” he said.
In this sense, the manager specified that in order to travel to Canada it is necessary for Mexican passengers to have a negative PCR test for Covid-19, as well as to have the complete vaccination scheme of Pfizer, Moderna, AstraZeneca or Johnson & Johnson (Janssen ).